Physician profile
Amy R Rampley
NPI 1134122492
$2,563.39
in general payments reported to CMS, 2019-2025
22 companies · $168 in 2025
The $168 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $270 · 2021: $751 · 2022: $386 · 2023: $408 · 2024: $323 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $899.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $369.74 | 2020-2022 | |
| Tris Pharma INC | $312.86 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $310.25 | 2020-2024 | Jornay Pm |
| Pfizer INC. | $256.68 | 2019-2024 | |
| Cranial Technologies, INC | $243.43 | 2019-2025 | Doc Band |
| Sanofi-Aventis U.S. LLC | $150.90 | 2024 | |
| Merck Sharp & Dohme LLC | $146.58 | 2021-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Supernus Pharmaceuticals, INC. | $145.49 | 2021-2023 | Qelbree |
| Sanofi Pasteur INC. | $97.69 | 2020-2024 | |
| Corium, LLC | $78.18 | 2021-2025 | Azstarys |
| Sobi, INC | $76.92 | 2019-2022 | |
| Neos Therapeutics, LP | $69.15 | 2019-2020 | |
| Organon LLC | $67.71 | 2023 | Nexplanon |
| Glaxosmithkline, LLC. | $40.26 | 2021-2023 | Bexsero |
| Seqirus USA INC | $35.93 | 2023-2025 | Flucelvax, Flucelvax Quadrivalent |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $33.36 | 2024 | Ycanth |
| Abbott Laboratories | $32.13 | 2025 | Id Now Instrument |
| Kaleo, INC. | $28.78 | 2023 | Auvi-Q |
| Lnhc, INC | $19.48 | 2025 | Zelsuvmi |
| Kowa Pharmaceuticals America, INC. | $16.91 | 2024 | Zoryve |
| Phadia US INC. | $16.02 | 2025 | Immunocap |
| Shire North American Group INC | $14.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Rampley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.